Drugs / CC-1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05646550 | Nov 2022 → Dec 2025 overdue | prostate cancer | University Hospital Tuebingen | Recruiting | No outcome recorded |
| Phase 1 | NCT04104607 | Nov 2019 → Dec 2025 overdue | castration-resistant prostate carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04496674 | Feb 2022 → May 2023 | squamous cell lung carcinoma | German Cancer Research Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04104607 ↗ |
| Action | Deplete | “CC-1 can elicit repeated target cell elimination by cytotoxic T cells” NCT04104607 ↗ |
| Route | Intravenous | “short-term intravenous infusion (3 hours)” NCT05646550 ↗ |